Pages that link to "Q86546620"

The following pages link to Xinan Sheng (Q86546620):

Displaying 15 items.

• Chinese guidelines on the management of renal cell carcinoma (2015 edition) (Q26772206) (← links)
• Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification (Q27851656) (← links)
• Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib (Q33419526) (← links)
• Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis (Q33430139) (← links)
• GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. (Q39516216) (← links)
• Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. (Q41573031) (← links)
• Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. (Q50498244) (← links)
• Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. (Q52739376) (← links)
• [Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma]. (Q53208703) (← links)
• RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma (Q64086083) (← links)
• Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study (Q89187696) (← links)
• First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data (Q90607746) (← links)
• Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial (Q92562893) (← links)
• Development of 99mTc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine (Q93138065) (← links)
• Open-label, multicenter, phase 2 study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma (Q101241953) (← links)